Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation;Marcadores séricos de fibrosis hepática en pacientes con hepatitis crónica C. Valor pronóstico de los marcadores no invasivos de fibrosis en el trasplante de hígado

Gastroenterologia y Hepatologia

Volumn 35, Issue SUPPL.2, 2012, Pages 17-22

  Crespo, Gonzalo ^a   Forns, Xavier ^a   Navasa, Miquel ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

APRI; Cirrhosis; ELF; FibroTest; Forns; Significant fibrosis

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ANTIVIRAL THERAPY; ARTICLE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER TRANSPLANTATION; PREDICTIVE VALUE; PROGNOSIS; RECURRENT INFECTION; SEROLOGY; BLOOD; COMPLICATION; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS;

BIOLOGICAL MARKERS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROGNOSIS;

EID: 84872043910     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/S0210-5705(12)70045-6     Document Type: Article

References (38)

1. Martínez S.M., Crespo G., Navasa M., Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-335.
2. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the Study of the Liver.
3. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
4. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martínez-Bauer E., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36(4 Pt 1):986-992.
5. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
6. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075. MULTIVIRC Group.
7. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713. European Liver Fibrosis Group.
8. Lin Z.H., Xin Y.N., Dong Q.J., Wang Q., Jiang X.J., Zhan S.H., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011, 53:726-736.
9. Poynard T., Morra R., Halfon P., Castera L., Ratziu V., Imbert-Bismut F., et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007, 7:40.
10. Guha I.N., Parkes J., Roderick P., Chattopadhyay D., Cross R., Harris S., et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47:455-460.
11. Parkes J., Guha I.N., Roderick P., Harris S., Cross R., Manos M.M., et al. Enhanced Liver Fibrosis (ELF.test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011, 18:23-31.
12. Guechot J., Trocme C., Renversez J.C., Sturm N., Zarski J.P., HC ANRS. Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C. Clin Chem Lab Med 2012, 50:693-699. EP 23 Fibrostar Study Group.
13. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012, 142:1293-1302. e4.
14. Sebastiani G., Halfon P., Castera L., Pol S., Thomas D.L., Mangia A., et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009, 49:1821-1827.
15. Bourliere M., Penaranda G., Renou C., Botta-Fridlund D., Tran A., Portal I., et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006, 13:659-670.
16. Leroy V., Hilleret M.N., Sturm N., Trocme C., Renversez J.C., Faure P., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:775-782.
17. Boursier J., De Ledinghen V., Zarski J.P., Rousselet M.C., Sturm N., Foucher J., et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011, 106:1255-1263.
18. Boursier J., Vergniol J., Sawadogo A., Dakka T., Michalak S., Gallois Y., et al. The combination of a blood test and FibroScan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009, 29:1507-1515.
19. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
20. Castera L., Sebastiani G., Le Bail B., De Ledinghen V., Couzigou P., Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010, 522:191-198.
21. Crespo G., Fernández-Varo G., Marino Z., Casals G., Miquel R., Martínez S.M., et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol 2012, 57:281-287.
22. Benlloch S., Berenguer M., Prieto M., Rayon J.M., Aguilera V., Berenguer J. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl 2005, 11:456-462.
23. Benlloch S., Heredia L., Barquero C., Rayon J.M., Pina R., Aguilera V., et al. Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. Liver Transpl 2009, 15:1798-1807.
24. Toniutto P., Fabris C., Bitetto D., Falleti E., Avellini C., Rossi E., et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol 2007, 22:1904-1908.
25. Cross T.J., Calvaruso V., Foxton M.R., Manousou P., Quaglia A., Grillo F., et al. A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. J Viral Hepat 2010, 17:640-649.
26. Carrión J.A., Fernández-Varo G., Bruguera M., García-Pagan J.C., García-Valdecasas J.C., Pérez-del-Pulgar S., et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010, 138:147-158. e1.
27. Blasco A., Forns X., Carrión J.A., García-Pagan J.C., Gilabert R., Rimola A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006, 43:492-499.
28. Friedrich-Rust M., Ong M.F., Martens S., Sarrazin C., Bojunga J., Zeuzem S., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008, 134:960-974.
29. Carrión J.A., Navasa M., Bosch J., Bruguera M., Gilabert R., Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006, 12:1791-1798.
30. Harada N., Soejima Y., Taketomi A., Yoshizumi T., Ikegami T., Yamashita Y., et al. Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation 2008, 85:69-74.
31. Corradi F., Piscaglia F., Flori S., D'Errico-Grigioni A., Vasuri F., Tame M.R., et al. Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis 2009, 41:217-225. Bologna Liver Transplantation Group.
32. Masuzaki R., Yamashiki N., Sugawara Y., Yoshida H., Tateishi R., Tamura S., et al. Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography. Scand J Gastroenterol 2009, 44:1115-1120.
33. Beckebaum S., Iacob S., Klein C.G., Dechene A., Varghese J., Baba H.A., et al. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. Transplantation 2010, 89:983-993.
34. Kamphues C., Lotz K., Rocken C., Berg T., Eurich D., Pratschke J., et al. Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients. Clin Transplant 2010, 24:652-659.
35. Prieto M., Berenguer M., Rayón J.M., Córdoba J., Arguello L., Carrasco D., et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999, 29:250-256.
36. Carrión J.A., Torres F., Crespo G., Miquel R., García-Valdecasas J.C., Navasa M., et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010, 51:23-34.
37. Rigamonti C., Donato M.F., Fraquelli M., Agnelli F., Ronchi G., Casazza G., et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. Gut 2008, 57:821-827.
38. Pungpapong S., Nunes D.P., Krishna M., Nakhleh R., Chambers K., Ghabril M., et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008, 14:1294-1302.